Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shandong Weigao Group Medical Polymer Co ( (HK:1066) ) just unveiled an announcement.
Shandong Weigao Group Medical Polymer Company Limited announced that its extraordinary general meeting held on 19 December 2025 approved all resolutions by poll, including framework agreements for purchases and logistic support services, the reappointment of independent non-executive director Li Qiang, and a change in company type. The strong shareholder support—despite required abstentions by controlling shareholder Weigao Holding and its associates on the related-party framework agreements—clears the way for the group to proceed with its intra-group procurement and logistics arrangements, reinforces its board structure, and enables a corporate restructuring step that may have implications for its future regulatory positioning and operational flexibility.
The most recent analyst rating on (HK:1066) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
More about Shandong Weigao Group Medical Polymer Co
Shandong Weigao Group Medical Polymer Company Limited is a PRC-incorporated medical device manufacturer focusing on medical polymer products. The company is listed in Hong Kong and operates through both H shares and domestic shares, with a significant base of institutional and controlling shareholders participating in corporate governance decisions via general meetings.
Average Trading Volume: 14,369,772
Technical Sentiment Signal: Sell
Current Market Cap: HK$23.34B
See more insights into 1066 stock on TipRanks’ Stock Analysis page.